Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC

AIM: We evaluated the efficacy of a novel switch protocol for EGFR-TKIs for EGFR mutation-positive NSCLC. MATERIALS & METHODS: Clinical records were collected from the patients who had received one of two sequential combination strategies of EGFR-TKIs: Salvage use of osimertinib for T790M-mediat...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Lung Cancer Manag
Autores principales: Imamura, Fumio, Inoue, Takako, Kunimasa, Kei, Kubota, Aki, Kuhara, Hanako, Tamiya, Motohiro, Nishino, Kazumi, Kimura, Madoka, Kuno, Kika, Kawachi, Hayato, Kumagai, Toru
Formato: Artigo
Lenguaje:Inglês
Publicado: Future Medicine Ltd 2020
Materias:
Short Communication
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7186852/
https://ncbi.nlm.nih.gov/pubmed/32346403
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/lmt-2020-0005
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares